- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06061627
A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD (BATTLE)
A Randomized Controlled Trial of Left Bundle brAnch opTimized Cardiac Resynchronization Therapy Versus conventionaL Bi-vEntricular Pacing in Heart Failure Patients With Nonspecific Intraventricular Conduction Delay
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cardiac resynchronization therapy is a standardized treatment strategy for patients with chronic heart failure complicated by wide QRS waves. With the continuous development of physiological pacing technology, traditional cardiac resynchronization therapy, namely biventricular pacing technology, is constantly challenged. Left bundle branch area pacing (LBBAP), as the main method of physiological pacing technology, is currently increasingly widely used in clinical practice. In recent years, research has mainly focused on heart failure patients with wide QRS waves such as non ischemic cardiomyopathy and typical left bundle branch block (LBBB). The recently published LBBP-RESYNC study was a randomized controlled study comparing left bundle branch pacing (LBBP) and biventricular pacing. The results showed that LBBP can achieve better improvement in left ventricular function compared to traditional biventricular pacing.
Compared with patients with typical LBBB, traditional biventricular pacing synchronized treatment is less effective in chronic heart failure patients accompanied by intraventricular block (NICD), which is closely related to the electrophysiological mechanism of LBBB. The blocking site of typical LBBB is generally located within the His bundle to the proximal end of the left bundle branch, while the distal end of the left bundle branch is relatively healthy. Therefore, LBBP can completely correct this type of LBBB and significantly narrow the QRS wave; The electrophysiological mechanism of NICD is relatively complex, and there may be multiple blocking sites, and LBBP cannot be completely corrected. How to improve the treatment efficacy and clinical prognosis of chronic heart failure patients with NICD is an important scientific issue that urgently needs to be solved. It is unclear whether left bundle branch pacing technology can provide support for cardiac function in such patients.
Traditional biventricular pacing combines right ventricular and left epicardial pacing; LBBAP combined with left ventricular epicardial pacing, also known as LOT-CRT, is an innovative pacing method. This study aims to explore the application value of LBBAP in patients with chronic heart failure and NICD.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jiangang Zou
- Phone Number: 86-13605191407
- Email: jgzou@njmu.edu.cn
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recruiting
- The First Affiliated Hospital with Nanjing Medical University
-
Contact:
- Jiangang Zou
- Phone Number: +8613605191407
- Email: jgzou@njmu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ischemic or non ischemic cardiomyopathy
- Optimal medical therapy for at lest 3 months
- NYHA class II-IV
- LVEF≤35% as assessed by echocardiography
- Sinus rhythm (may have paroxysmal atrial fibrillation)
- QRS duration ≥ 150ms
- Intraventricular block (NICD), QRS morphology is neither LBBB nor RBBB
Exclusion Criteria:
- Valvular heart disease that requires or has undergone surgical intervention
- After mechanical tricuspid valve replacement
- Persistent or permanent atrial fibrillation or atrial flutter
- Second or third degree atrioventricular block
- Have a history of acute myocardial infarction within 3 months prior to enrollment
- Patient's expected survival time is less than 12 months
- Pregnant or planned to conceive
- Ventricular septal hypertrophy (ventricular septal thickness exceeds 15mm at the end of diastole)
- Patients with simple and persistent left superior vena cava
- Patients with existing pacemaker implantation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: LOT-CRT group
In this arm, an right artrial (RA) lead, an implantable cardioverter defibrillator (ICD) lead and a LV pacing lead are placed are conventionally implanted. A left bundle branch pacing(LBBP) lead is attempted to be placed. |
In addition to the leads implanted in BiVP group, it is also necessary to implant the left bundle branch area pacing(LBBAP) leads LBBAP includes LBBP and LVSP. LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:
If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP). |
|
Active Comparator: BiVP group
In this arm, an RA lead , an ICD lead and a LV pacing lead are placed.
|
Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Left ventricular ejection fraction(LVEF)
Time Frame: Baseline; 6-month follow-up
|
Changes from baseline LVEF(unit: %) assessed by echocardiography at follow-up
|
Baseline; 6-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Paced QRS duration
Time Frame: Postoperative day 1; 1-month,3-month and 6-month follow-up
|
Paced QRS duration is evaluated postoperative day 1 and 1 months, 3 months and 6 months after implantation.
|
Postoperative day 1; 1-month,3-month and 6-month follow-up
|
|
A combined clinical endpoint of all-cause mortality and heart failure hospitalization,
Time Frame: 6-month follow-up
|
Including date and number of all-cause mortalityand heart failure hospitalization,
|
6-month follow-up
|
|
Left ventricular end systolic volume(LVESV)
Time Frame: Baseline; 3-month, 6-month follow-up
|
Changes from baseline LVESV(unit: mL) assessed by echocardiography at follow-up
|
Baseline; 3-month, 6-month follow-up
|
|
Left ventricular end diastolic volume(LVEDV)
Time Frame: Baseline; 3-month, 6-month follow-up
|
Changes from baseline LVEDV(unit: mL) assessed by echocardiography at follow-up
|
Baseline; 3-month, 6-month follow-up
|
|
Left ventricular end systolic diameter(LVESD)
Time Frame: Baseline; 3-month, 6-month follow-up
|
Changes from baseline LVESD(unit: mm) assessed by echocardiography at follow-up
|
Baseline; 3-month, 6-month follow-up
|
|
Left ventricular end diastolic diameter(LVEDD)
Time Frame: Baseline; 3-month, 6-month follow-up
|
Changes from baseline LVEDD(unit: mm) assessed by echocardiography at follow-up
|
Baseline; 3-month, 6-month follow-up
|
|
Change in Quality Of Life Questionnaire score between baseline and follow-up
Time Frame: Baseline; 3-month, 6-month follow-up
|
Reflect the effect of cardiac funtion on quality of life, and higher scores represent a worse outcome
|
Baseline; 3-month, 6-month follow-up
|
|
Changes in New York Heart Association Heart Function Classification between baseline and follow-up
Time Frame: Baseline; 3-month, 6-month follow-up
|
The higher the classification, the more severe the heart failure symptoms(four levels: I, II, III and IV)
|
Baseline; 3-month, 6-month follow-up
|
|
Changes in 6-minute Walk Distance between baseline and follow-up
Time Frame: Baseline; 3-month, 6-month follow-up
|
Distance that a participant walk within 6 minutes
|
Baseline; 3-month, 6-month follow-up
|
|
Changes in concentration of NT-proBNP in blood between baseline and follow-up
Time Frame: Baseline; 3-month, 6-month follow-up
|
Blood test is performed at each time frame to determine the concentration of NT-proBNP(unit: pg/mL)
|
Baseline; 3-month, 6-month follow-up
|
|
Incidence of stroke events
Time Frame: 6-month follow-up
|
Including date and number of stroke
|
6-month follow-up
|
|
A combined arrhythmia endpoint of new-onset atrial fibrillation and malignant ventricular arrhythmia
Time Frame: 6-month follow-up
|
Including date and number of new-onset atrial fibrillation and malignant ventricular arrhythmia
|
6-month follow-up
|
|
Success rate of LBBAP implantation Success rate of LBBAP implantation Success rate of LBBAP implantation Success rate of LBBAP implantation Success rate of LBBAP implantation
Time Frame: Operative day
|
Success rate of LBBAP in LOT-CRT group
|
Operative day
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jiangang Zou, The First Affiliated Hospital with Nanjing Medical University
- Principal Investigator: Yangang Su, Shanghai Zhongshan Hospital
Publications and helpful links
General Publications
- Wang Y, Zhu H, Hou X, Wang Z, Zou F, Qian Z, Wei Y, Wang X, Zhang L, Li X, Liu Z, Xue S, Qin C, Zeng J, Li H, Wu H, Ma H, Ellenbogen KA, Gold MR, Fan X, Zou J; LBBP-RESYNC Investigators. Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy. J Am Coll Cardiol. 2022 Sep 27;80(13):1205-1216. doi: 10.1016/j.jacc.2022.07.019.
- Jastrzebski M, Moskal P, Huybrechts W, Curila K, Sreekumar P, Rademakers LM, Ponnusamy SS, Herweg B, Sharma PS, Bednarek A, Rajzer M, Vijayaraman P. Left bundle branch-optimized cardiac resynchronization therapy (LOT-CRT): Results from an international LBBAP collaborative study group. Heart Rhythm. 2022 Jan;19(1):13-21. doi: 10.1016/j.hrthm.2021.07.057. Epub 2021 Jul 30.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FirstNanjingMU005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Umeå UniversityRegion NorrbottenNot yet recruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureSweden
-
University of Health Sciences LahoreRecruitingAcute Decompensated Heart Failure | Heart Failure, Diastolic | Heart Failure, SystolicPakistan
-
Indiana UniversityRecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)United States
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Lakeland Regional Health Systems, Inc.RecruitingHeart Failure | Heart Failure Acute | Acute Heart Failure (AHF) | Heart Failure - NYHA II - IVUnited States
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Eli Lilly and CompanyNot yet recruitingHeart Failure | Heart Failure, Diastolic | Heart Failure, SystolicUnited States, Japan
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
Clinical Trials on LOT-CRT group
-
Medtronic Cardiac Rhythm and Heart FailureNot yet recruitingHeart Failure | Systolic Bundle Branch Block, Left
-
Abbott Medical DevicesTerminatedHeart FailureUnited States
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Manhattan Psychiatric CenterNathan Kline Institute for Psychiatric ResearchCompletedSchizophreniaUnited States
-
Michele BrignoleCompleted
-
Merck Sharp & Dohme LLCWithdrawn
-
Bavarian NordicEmergent BioSolutionsCompletedCholeraUnited States, Australia
-
Sinovac Biotech Co., LtdCompleted
-
Oregon Research InstituteCompletedSubstance Use Disorders | Treatment RefusalUnited States
-
Merck Sharp & Dohme LLCCompleted